Michael Brian Bell sold $8.3M of GH
Chief Financial Officer at Guardant Health, Inc.. 80,362 shares at an average of $103.14, traded Dec 5, 2025, filed Dec 8, 2025.
Score components
- +22RoleCFO
- +25Trade size$8.3M at market
- +20Share of holdings soldSold 74% of holdings
- +15Cluster10 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001702824-25-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 5, 2025 | MOption exercise Common Stock | +29,382 | $32.86 | $965k | 81,509 | Dec 8, 2025 |
| Dec 5, 2025 | MOption exercise Common Stock | +26,905 | $28.37 | $763k | 108,414 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -8,033 | $101.42 | $815k | 100,381 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -22,891 | $102.11 | $2.3M | 77,490 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -7,567 | $103.26 | $781k | 69,923 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -11,978 | $103.96 | $1.2M | 57,945 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -250 | $105.82 | $26k | 57,695 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -5,568 | $106.68 | $594k | 52,127 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -3,267 | $101.46 | $331k | 48,860 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -8,774 | $102.11 | $896k | 40,086 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -2,533 | $103.24 | $262k | 37,553 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -5,027 | $103.96 | $523k | 32,526 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -3,284 | $106.70 | $350k | 29,242 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -1,190 | $107.26 | $128k | 28,052 | Dec 8, 2025 |
| Dec 5, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -29,382 | $0.00 | $0 | 7,137 | Dec 8, 2025 |
| Dec 5, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -26,905 | $0.00 | $0 | 10,421 | Dec 8, 2025 |
Related signals
Other insiders at Guardant Health, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | Guardant Health, Inc. | Alex M Azar II director | $145k 826 shares | -50% | |
| 55Moderate | Guardant Health, Inc. | Darya Chudova Chief Technology Officer | $1.4M 7,738 shares | -10% | |
| 65Notable | Guardant Health, Inc. | Steve E. Krognes director | $1.2M 6,674 shares | -46% | |
| 0Weak | Guardant Health, Inc. | Musa Tariq director | $20k 116 shares | -1% | |
| 50Moderate | Guardant Health, Inc. | Kumud Kalia Chief Information Officer | $632k 4,000 shares | -9% | |
| 35Weak | GHsell Guardant Health, Inc. | Michael Brian Bell Chief Financial Officer | $257k 2,000 shares | -4% | |
| 56Moderate | GHsell Guardant Health, Inc. | Ian T Clark director | $735k 6,876 shares | -70% | |
| 15Weak | Guardant Health, Inc. | Musa Tariq director | $31k 348 shares | -4% | |
| 35Weak | Guardant Health, Inc. | Michael Brian Bell Chief Financial Officer | $261k 3,000 shares | -6% | |
| 45Moderate | Guardant Health, Inc. | Medina Manuel Hidalgo director | $119k 1,300 shares | -52% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.